Neurobiology and Therapeutic Potential of Klotho
Neurobiology and Therapeutic Potential of Klotho
批准号:
8896891
负责人:
Lennart Mucke
金额:
$70.85万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-08-01 至 2019-07-31
关键词:
AcuteAddressAffectAgeAgingAlzheimer&aposs DiseaseAmyloidAmyloid beta-Protein PrecursorBiologicalBiological Neural NetworksBlood - brain barrier anatomyBrainBrain regionCell Culture TechniquesCerebrospinal FluidCognitionDataDevelopmentDiseaseEpithelial CellsFunctional disorderGlutamate ReceptorHealthHippocampus (Brain)HumanImpaired cognitionIntegral Membrane ProteinKidneyKnowledgeLearningLengthLifeLongevityMediatingMemoryMusN-Methyl-D-Aspartate ReceptorsNeuraxisNeurobiologyNeurodegenerative DisordersNeuronsNeurophysiology - biologic functionPathway interactionsPeripheralPlayPopulationProductionProteinsRelative (related person)Risk FactorsRoleSerumSignal PathwayStagingStructure of choroid plexusSynapsesSynaptic plasticityTestingTherapeuticTimeTransgenic MiceVariantVascular Endothelial Growth Factor Receptorage relatedcognitive functioncognitive testingfascinatefibroblast growth factor 23follow-upimprovedkidney cellklotho proteinmiddle agemouse modelnervous system disordernetwork dysfunctionpostsynapticpreventprotein expressionreceptorreceptor functionsynaptic function
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Cognitive functions such as learning and memory are of fundamental biological importance and diseases that affect these functions are among the most challenging biomedical problems of our time. We recently obtained evidence indicating that elevating levels of the pleotropic protein klotho enhances cognitive functions in mice and humans and can prevent synaptic and cognitive impairments in a transgenic mouse model simulating key aspects of Alzheimer's disease (AD). Klotho is a class I transmembrane protein whose ectodomain is released by proteolytic cleavage. In the periphery, it is produced predominantly by the kidney. Within the central nervous system (CNS), it is produced predominantly by the choroid plexus, with lower levels of expression seen in specific neuronal populations, particularly in the hippocampus. While diverse lines of evidence suggest that klotho delays aging and aging-related diseases, the functions it fulfills in the CNS and the roles it migh play in neurological disease are largely unknown. In our preliminary studies, increasing klotho production throughout the body of transgenic mice enhanced learning and memory not only in middle-aged and old mice, but also in young mice. Moreover, heterozygous human carriers of a KLOTHO variant (KL-VS) had elevated levels of klotho in the serum and performed better in a battery of cognitive tests than non-carriers. Again, this klotho effect was seen across a wide age range. Global klotho elevation also prevented AD-related synaptic, neural network and cognitive dysfunctions in human amyloid precursor protein (hAPP) transgenic mice. We hypothesize that klotho improves neural functions in both normal and diseased brains through a mechanism that is independent of aging. We also hypothesize that augmenting klotho or its effects can counteract the pathogenic effects of elevated amyloid-? (A?) levels in the brain and may help prevent AD. To test these hypotheses and help unravel the functions of this fascinating protein in the brain, we propose three specific aims. Aim 1 will explore whether increasing the peripheral production of klotho improves synaptic and cognitive functions or whether klotho levels must be elevated within the blood-brain barrier to achieve these beneficial effects. It will
also ascertain the relative importance of secreted klotho released from choroid plexus epithelial cells into the cerebrospinal fluid versus full-length klotho expressed in specific neuronal populations. Aim 2 will examine the functional importance of klotho expression in the CNS at different life stages and define the potential pathogenic impact of klotho depletion from the brain, which occurs with aging and is prominent in humans with AD. Aim 3 will explore potential mechanisms by which increased klotho levels enhance synaptic and cognitive functions, with a particular emphasis on glutamate receptors and related signaling pathways. The proposed studies will fill important knowledge gaps and could provide critical guidance for the development of klotho-related therapeutics in independent projects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Transcriptomic and Proteomic Analysis of Tau-dependent E/I Imbalance
-
批准号:10789541
-
项目类别:
-
资助金额:$51.98万
-
财政年份:2023
-
负责人:Lennart Mucke
-
依托单位:
Roles of TREM2 and TYROBP in AD-related Network Hyperexcitability
-
批准号:10718004
-
项目类别:
-
资助金额:$283.31万
-
财政年份:2023
-
负责人:Lennart Mucke
-
依托单位:
Core A: Administrative Core
-
批准号:10461840
-
项目类别:
-
资助金额:$19.84万
-
财政年份:2021
-
负责人:Lennart Mucke
-
依托单位:
Project 3: Roles of Tau Levels, Sequence and Interactors in Neural Network Dysfunction of Alzheimer's Disease
-
批准号:10670346
-
项目类别:
-
资助金额:$110.73万
-
财政年份:2021
-
负责人:Lennart Mucke
-
依托单位:
Core A: Administrative Core
-
批准号:10670332
-
项目类别:
-
资助金额:$17.36万
-
财政年份:2021
-
负责人:Lennart Mucke
-
依托单位:
Project 3: Roles of Tau Levels, Sequence and Interactors in Neural Network Dysfunction of Alzheimer's Disease
-
批准号:10461845
-
项目类别:
-
资助金额:$86.76万
-
财政年份:2021
-
负责人:Lennart Mucke
-
依托单位:
Core A: Administrative Core
-
批准号:10271124
-
项目类别:
-
资助金额:$17.64万
-
财政年份:2021
-
负责人:Lennart Mucke
-
依托单位:
Project 3: Roles of Tau Levels, Sequence and Interactors in Neural Network Dysfunction of Alzheimer's Disease
-
批准号:10271128
-
项目类别:
-
资助金额:$88.8万
-
财政年份:2021
-
负责人:Lennart Mucke
-
依托单位:
Evolving CRISPR-based platforms for the discovery of Alzheimer relevant neurodegenerative pathways
-
批准号:10056618
-
项目类别:
-
资助金额:$51.98万
-
财政年份:2020
-
负责人:Lennart Mucke
-
依托单位:
Neural network and immune cell dysfunctions in Alzheimer's disease pathogenesis
-
批准号:9766119
-
项目类别:
-
资助金额:$453.83万
-
财政年份:2019
-
负责人:Lennart Mucke
-
依托单位:
Neural network and immune cell dysfunctions in Alzheimer's disease pathogenesis
-
批准号:10077445
-
项目类别:
-
资助金额:$47.25万
-
财政年份:2019
-
负责人:Lennart Mucke
-
依托单位:
Identification and Development of Tau-Lowering Small-Molecule Drugs
-
批准号:9893521
-
项目类别:
-
资助金额:$170.39万
-
财政年份:2019
-
负责人:Lennart Mucke
-
依托单位:
Therapeutic Potential and Mechanisms of Tau Reduction in Autism Models
-
批准号:10394402
-
项目类别:
-
资助金额:$71.71万
-
财政年份:2018
-
负责人:Lennart Mucke
-
依托单位:
Therapeutic Potential and Mechanisms of Tau Reduction in Autism Models
-
批准号:10158269
-
项目类别:
-
资助金额:$71.71万
-
财政年份:2018
-
负责人:Lennart Mucke
-
依托单位:
Therapeutic Potential and Mechanisms of Tau Reduction in Autism Models
-
批准号:9910231
-
项目类别:
-
资助金额:$71.71万
-
财政年份:2018
-
负责人:Lennart Mucke
-
依托单位:
Effect of Aging on Efficacy of Alzheimer-focused Therapeutic Strategies
-
批准号:9978935
-
项目类别:
-
资助金额:$16.85万
-
财政年份:2016
-
负责人:Lennart Mucke
-
依托单位:
Effect of Aging on Efficacy of Alzheimer-focused Therapeutic Strategies
-
批准号:9203583
-
项目类别:
-
资助金额:$3.24万
-
财政年份:2016
-
负责人:Lennart Mucke
-
依托单位:
Neurobiology and Therapeutic Potential of Klotho
-
批准号:9096912
-
项目类别:
-
资助金额:$70.85万
-
财政年份:2014
-
负责人:Lennart Mucke
-
依托单位:
Behavioral Core
-
批准号:8386647
-
项目类别:
-
资助金额:$81.1万
-
财政年份:2011
-
负责人:Lennart Mucke
-
依托单位:
PHOSPHOPROTEOMIC ANALYSIS OF SYNAPTIC PROTEINS IN ALZHEIMER DISEASE MOUSE MODELS
-
批准号:8363789
-
项目类别:
-
资助金额:$2.12万
-
财政年份:2011
-
负责人:Lennart Mucke
-
依托单位:
海外基金